ARCHIVES

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

ASCO Releases Three Guidelines For Cancer Survivorship Care

April 25, 2014

FDA Updates Safety Labeling Of 5-Alpha Reductase Inhibitors

June 24, 2011

Fisher Unable To Answer Key Questions, Blames NCI, A Second Hearing On NSABP

June 24, 1994

Ohio Center Helps Women Stop Smoking, Reduce Cervical Cancer Risk

October 29, 2004

CTEP Starts New Effort to Bring Minorities Into Clinical Trials

March 2, 1990

NSABP Submits Appeal To NIH To Reverse Cancellation Of P-4 Chemoprevention Trial.

August 10, 2007